Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These ...

Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...

BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences (NASDAQ:ROIV), reported the exercise of a large sell of company stock options.

This page features the latest news about the Roivant Sciences stock. Roivant Sciences presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat Pulmovant, a Roivant ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...